ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Tripos Sells Its Discovery R&D Unit

January 8, 2007 | APPEARED IN VOLUME 85, ISSUE 2

Tripos completed plans for its liquidation last week with the announcement that it will sell its Discovery Research business in Bude, England, to Provid Pharmaceuticals, in North Brunswick, N.J., for $2 million. Provid provides medicinal chemistry research services to the biotech and pharmaceutical industries and will, according to Tripos, retain the Bude staff. Late last year, Tripos announced the sale of its Discovery Informatics business in St. Louis to Vector Capital, in San Francisco, for $25.6 million. CEO John McAlister says the sale to Vector, which specializes in information technology buyouts, will allow the informatics business to operate as a private company "with greater access to growth capital."

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment